JP Morgan analysts believe Ogsiveo's broad label is an outri...
JP Morgan analysts believe Ogsiveo's broad label is an outright victory for SpringWorks. They see the drug's global blockbuster potential and notice the company's research into its applicability to certain ovarian tumors and multiple myeloma.
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
john 严 : You think too much